


PHARMACEUTICAL 2020

Acer Therapeutics Inc. Rank 232 of 358







PHARMACEUTICAL 2020

Acer Therapeutics Inc. Rank 232 of 358



The relative strengths and weaknesses of Acer Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acer Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 92% points. The greatest weakness of Acer Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 140% points.

The company's Economic Capital Ratio, given in the ranking table, is 18%, being 19% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	12,885
Cost of Goods Sold	0
Intangible Assets	7,647
Liabilities, Current	2,769
Liabilities, Non-Current	326
Other Assets	739
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	479
Other Revenues	0
Property and Equipment	194
Research and Development	13,851
Selling, General and Administrative Expense	16,046

Output Variable	Value in 1000 USD
Assets	21,466
Liabilities	3,095
Expenses	29,897
Revenues	0
Stockholders Equity	18,370
Net Income	-29,418
Comprehensive Net Income	-29,418
Economic Capital Ratio	18%

